Lazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 6 March 2025, approved lazertinib (brand name Lazcluze) for adults with non-small cell lung cancer that has spread to other…